purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation mck earnings call period ending march image source motley fool mckesson mck q earnings callmay pm etcontents prepared remark question answer call participant prepared remark operatorwelcome mckessons fourth quarter fiscal earnings conference call please advised today conference recorded time would like turn call rachel rodriguez vp investor relation please go aheadrachel rodriguez vice president investor relation thank operator good afternoon welcome everyone mckessons fourth quarter fiscal earnings call today joined brian tyler chief executive officer britt vitalone chief financial officer brian lead followed britt move questionandanswer session today discussion include forwardlooking statement forecast mckessons operation future result please refer cautionary statement today earnings release presentation slide available website investormckessoncom risk factor section recent annual periodic sec filing additional information concerning risk factor could cause actual result materially differ forwardlooking statement information nongaap financial measure discus webcast including reconciliation measure gaap result found today earnings release presentation slide presentation slide also include summary result quarter guidance assumptionswith let turn brian brian tyler chief executive officer thank rachel good afternoon everyone thanks joining call afternoon today reported fiscal fourthquarter result marking close strong fiscal want thank mckesson employee terrific effort course year together drove business achieved significant progress advancing mission strategy fiscal consolidated revenue grew billion adjusted earnings per diluted share increased exceeding expectation set beginning fiscal year pleased growth across enterprise supported differentiated portfolio asset innovative solution deep commitment quality operational excellence particularly excited opportunity within strategic growth pillar oncology biopharma service year saw record expansion yous oncology network strong market demand access affordability adherence solution going start remark today review company priority going hand britt take u detail financial performance outlook fiscal take away u today confidence strength underlying business commitment continue carrying strategy momentum next year first company priority want touch focus people culture past year made continued progress transforming mckesson diversified healthcare service company requires u embrace new idea lead forefront innovation honored recognized one america innovative company fortune continue strengthen innovative culture essential growth strategy overall recently also named one america greatest workplace woman newsweek top woman employer diversity com medium pleased see companywide effort continue recognized externally also really quite impressed commitment leadership exhibited many mckesson employee initiative take support create open collaborative culture moving two strategic pillar oncology biopharma service pivotal asset unlock tremendous value bring significant benefit customer stakeholder year building portfolio asset around oncology spanning distribution related therapy practice management oncology data insight valueadded service pleased meaningful expansion oncology asset reflected growth yous oncology network welcome four practice network fiscal year including regional cancer care associate cancer center kansa nashville oncology associate scri oncology partner addition new practice expands geographic footprint allows u provide service broader set provider importantly patient serve april network grown approximately provider site care across state grew provider network combination newly affiliated practice recruitment new provider existing practice saw organic growth provider practice extensive reach within community oncology setting yous oncology network treat million patient year addition practice management also provide clinical trial service communitybased practice expanded clinical trial capability formation joint venture operates name sarah cannon research institute sometimes referred scri past year practice yous oncology network participated clinical trial scri enrolling patient treatment study across various disease state february scri announced collaboration astrazeneca enhance delivery oncology clinical trial working together two party implement modern solution accelerate clinical trial delivery time line reduce site burden enhance trial enrollment within scaled provider network addition oncology differentiated growth priority biopharma service platform portfolio connected solution provides unique value proposition biopharma company help improve medication access affordability adherence fiscal saw strong growth prescription technology segment delivering growth adjusted operating profit importantly past year differentiated solution helped patient save billion brand specialty medication helped prevent approximately million prescription abandoned due affordability challenge help patient access medicine million time biopharma service platform built year strategic investment includes targeted acquisition accelerated growth strategy internal investment drove innovation enhanced capability one first asset acquired relay health foundational network service offer today familiar business help adjudicate prescription claim enable efficient delivery prescription drug connected pharmacy process billion transaction annually connectivity pharmacy provides u insight patient journey help u develop additional solution program like copay assist program digital coupon want provide customer claim switch solution robust platform connects key stakeholder delivers access affordability solution ultimately improves patient experience outcome let u move next priority driving sustainable core growth scaled durable asset pharmaceutical medicalsurgical distribution continue deliver sustainable growth core business fiscal yous pharmaceutical delivered solid result increase revenue increase adjusted operating profit remind high end longterm target segment support business growth evolving need customer continue invest infrastructure ensuring distribution asset technologically equipped maximize capacity efficiency still early stage investing capability artificial intelligence already developed tool algorithm apply ai supply chain enabling u move product quickly nimbly throughout distribution center generating cost saving continuing improve service level continue make targeted strategic investment support sustainable growth business core distribution business also complemented growing portfolio service solution around specialty oncology add differentiated market position support unique value proposition customer today excited talk strategic relationship optum started servicing portion optums business last year pleased get opportunity expand scope service starting july believe relationship strong testament differentiated capability service across pharmaceutical distribution sourcing oncology look forward opportunity serve grow customer including optum ass investment opportunity allocate resource across enterprise strive ensure decision align strategic priority mission improving healthcare every setting want become diversified healthcare service company also company enables positive change community drive impact april launched new initiative aimed advancing healthequity atrisk population underserved community long history working pharmacy provider community setting want leverage business resource expertise support growth enable better access healthcare many community project look identify address pharmacy desert resident faced significant challenge accessing essential pharmacy service chose avondale ohio pilot activation site help facilitate expedited path independent pharmacy ownership local community opened pharmacy past december opportunity personally experience joy live community appreciating something u take granted pharmacy near house look forward making lasting difference community like avondale future also support fund many charitable work mckesson foundation past year marked important milestone foundation celebrated th anniversary last year alone funded nearly organization grantmaking program disbursed approximately million onethird supported direct patient care assistance also pleased see continued increase employee participation impactful initiative fiscal mckesson employee put volunteer hour charity across yous canada truly proud achieved team support community live purpose advancing health outcome let pull together mckesson delivered performance initial expectation fiscal underpinned continued momentum across business finished year growing portfolio oncology biopharma service solution expanded core distribution business stronger culture unites u look ahead fiscal excited opportunity grow differentiated asset capability remain deeply committed strategy priority confident ability drive sustainable business growth generate attractive shareholder return team mckesson focused agile enter new fiscal year strength confidence brett hand youbritt vitalone chief financial officer great thank brian good afternoon everyone fiscal mark another year strong execution financial performance entered fiscal momentum deliver growth create value customer partner shareholder today discus fourth quarter fullyear fiscal result provide overview fiscal outlook comment today refer adjusted result unless state otherwise exiting fiscal solid performance delivering earnings per diluted share fourth quarter full year fourth quarter result line expectation earnings per diluted share guidance range provided third quarter earnings call demonstrating ability consistently execute company priority create longterm sustainable value shareholder full year excluding fiscal contribution covidrelated program mckesson venture adjusted operating profit grew adjusted eps increased result longrange target reflect strength product service operating execution let start review fiscal fourth quarter revenue increased billion led growth yous pharmaceutical segment resulting increased prescription volume including higher volume specialty product retail national account customer glp medication gross profit billion increase primarily result specialty distribution growth within yous pharmaceutical segment including leading plasma biologics business operating expense increased billion driven higher cost support growth across business quarter recorded reserve environmental matter per share increased remediation cost related mckessons former chemical business disposed several year ago environmental reserve recorded corporate segment operating profit billion flat prior year driven growth yous pharmaceutical segment offset increased corporate expense included previously outlined environmental reserve yearoveryear result also impacted anticipated lower contribution yous government covid program yous pharmaceutical medicalsurgical solution segment compared prior year adjusting covid program modest mckesson venture loss fiscal adjusted operating profit increased quarter moving line interest expense million increase driven higher shortterm borrowing commercial paper compared prior year higher shortterm borrowing resulted lower average cash balance part due impact change healthcare outage effective tax rate quarter line previous guidance driven discrete tax item fourth quarter diluted weighted average share outstanding million decrease year year wrapping consolidated result earnings per diluted share line implied earnings per diluted share provided thirdquarter earnings call represents decrease compared prior year fourth quarter result principally driven higher tax rate lower covid program contribution fiscal partially offset lower share count growth yous pharmaceutical segment turning fourth quarter segment result found slide starting yous pharmaceutical revenue billion increase driven increased prescription volume including higher volume specialty product retail national account customer glp medication previously guided glp medication continue show growth year year despite increase rate growth continues moderate quarter glp revenue billion increase approximately billion compared fiscal however glp revenue flat sequential basis quarter operating profit increased million driven growth distribution specialty product provider health system increased contribution generic program creative capability asset continued deliver robust value stakeholder prescription technology solution segment revenue billion flat prior year lower contribution thirdparty logistics business offset growth across technology service product primarily access solution within segment covermymeds continues deliver value partner increasing connectivity pharmacy provider payer biopharma manufacturer nextgeneration access affordability adherence solution automated integrated provider workflow result fourth quarter reflect organic growth across access solution including prior authorization service extended existing partnership biopharma manufacturer addition strength access solution yearoveryear performance also supported higher volume across affordability solution operating profit decreased million driven higher cost investment sustain momentum growth across biopharma service platform included incremental infrastructure investment cost deliver increasing level roi customer operating profit also impacted lower thirdparty logistics performance quarter compared prior year turning medicalsurgical solution revenue billion increase operating profit million flat versus prior year fourth quarter result reflect growth primary care extended care business including higher volume illness season testing partially offset lower contribution kitting storage distribution ancillary supply yous government covid program compared prior year reminder illness season unique depending onset severity various respiratory illness particular year next let address international result revenue billion increase operating profit million increase strong result driven higher pharmaceutical distribution volume canadian business compared prior year wrapping segment review corporate expense million quarter increase driven previously discussed environmental reserve higher technology infrastructure compliance spend let turn cash capital deployment found slide ended quarter billion cash cash equivalent fiscal year generated billion free cash flow including million capital expenditure included new existing distribution center well investment technology data analytics support growth priority quarter several customer impacted change healthcare outage delaying billing function claim payment outage created timing impact mckessons cash flow however impact le severe previously indicated continue focus capital deployment drive value stakeholder fiscal returned billion cash shareholder returned billion share repurchase average price per share approximately including million share repurchase fiscal fourth quarter additionally paid dividend million full year combining share repurchase dividend paid returned approximately free cash flow shareholder fiscal since beginning fiscal returned billion cash shareholder share repurchase dividend amount approximately billion returned share repurchase reducing total average share outstanding nearly strength balance sheet strong credit metric supported strong operating performance disciplined balanced financial policy recognized quarter recent moody credit rating upgrade baa arated two three major credit rating agency strong balance sheet consistently robust cash flow generation along disciplined capital allocation continues provide u financial flexibility invest growth initiative pursue strategic opportunity return capital shareholder maintaining durable capital structure let discus fiscal outlook breadth capability leading portfolio asset across oncology biopharma service led value creation customer partner shareholder last five year fiscal outlook continuation momentum let start segment anticipate yous pharmaceutical revenue increase operating profit increase propelled sustainable momentum core distribution business growth across oncology platform continue make investment core distribution network deliver efficiency value stakeholder strength value proposition highlighted recent agreement build existing pharmaceutical distribution partnership optum fiveyear contract begin july fiscal segment outlook incorporates stable growing prescription utilization trend bolstered growth generic sourcing program specialty distribution including leading plasma biologics business anticipate growth differentiated oncology platform breadth asset yous oncology network ontada sarah cannon research institute joint venture brian mentioned april yous oncology network grown approximately provider state pleased advancement made ontada sarah cannon research institute supporting mission advance cancer care pleased growth seeing yous pharmaceutical segment asset capability core distribution oncology platform continued accelerate growth prescription technology solution segment anticipate revenue increase operating profit increased outlook reflects organic growth across solution service expand extend partnership biopharma manufacturer increase number brand utilizing access affordability adherence program throughout fiscal continue see increased demand access affordability solution particularly related glp medication reminder mckessons prior authorization product serve majority brand glp medication product continue generate value partner looking ahead fiscal anticipate demand remain elevated yet lessen rate increase slower prior year glp medication medical surgical business remains well positioned leverage breadth depth service asset across alternate site care including growth primary care business comprehensive private label portfolio anticipate medical surgical solution revenue increase operating profit increase within primary care market anticipate continued growth lab solution specialty pharmaceutical scale sourcing distribution footprint propelled expansion growth private label portfolio providing superior value customer maintaining sound economics mckesson fiscal making investment segment support recent acquisition compile healthcare data platform capture aggregate data provide insight analytics biopharma believe initial use case across breadth medical surgical solution segment medical surgical solution segment broad relationship provider extensive data set meeting opportunity develop incremental value creation opportunity longer term increased opportunity integrate capability commercial application across oncology biopharma service platform investment deliver meaningful return segment enterprise fiscal anticipate investment account approximate operating profit headwind medical segment compared prior year finally international segment anticipate revenue increase operating profit increase year year diversified set asset within canadian business including scale distribution business continues support growth international segment continue make investment canadian technology footprint create custom integrated supply chain specialty drug reminder norway remains operating country europe entered agreement sell contribution related operation norway included fiscal outlook segment intend exit norway part completion european exit corporate segment anticipate expense range million million includes increased technology spend support growth business infrastructure compliance investment also continue invest data analytics including acceleration several investment artificial intelligence leveraging ai increase efficiency across operation increase automation productivity customer investment ai advanced technology play important role improving customer service provider productivity continue build tool across value chain increase speed success rate one example implementing ai oncology platform ehr contains structured data often sparsely entered patient longitudinal record instead unstructured data uploaded document providerauthored note used capture detail patient disease condition response treatment well many core clinical factor complete longitudinal patient record realworld research core variable required extracted unstructured data wellorganized database natural language process scalable solution achieve million document inaudible today growing rate million document per week application ai reduces clinician exhaustive burden finding related document care reimbursement workflow ultimately leading practice efficiency better patient care one example many using ai power insight deliver clinical financial value stakeholder pleased progress date work develop implement various ai technology remain committed increased investment extend leadership position deliver value partner stakeholder moving line anticipate interest expense approximately million million income attributable noncontrolling interest range million million anticipate fullyear effective tax rate range approximately reminder timing amount discrete tax item difficult predict therefore provide quarterly effective tax rate guidance turning cash flow capital deployment anticipate free cash flow approximately billion billion working capital metric resulting free cash flow vary quarter quarter impacted timing including day week mark close quarter guidance reflects plan repurchase approximately billion share fiscal result share repurchase activity estimate weighted average diluted share outstanding range approximately million million strength balance sheet operating cash flow provides financial flexibility incrementally invest organically inorganically growth well return capital shareholder wrapping fiscal guidance anticipate revenue growth operating profit growth compared prior year fiscal anticipate earnings per diluted share represents growth compared fiscal expect earnings per share heavily weighted toward second half fiscal year also anticipate first quarter lowest contribution reminder lower effective tax rate first quarter fiscal due discrete tax item summary see strength stability underlying fundamental across business sustained financial performance past several year bolstered strength financial position consistent operating execution leading compelling value creation customer partner shareholder pleased strong fiscal performance fiscal outlook reflects continued confidence operating profit growth momentum across segment business supplemented strength balance sheet strong financial position mckesson wellpositioned deliver strong result successfully execute strategic financial framework drive longterm sustainable growth stakeholder move qa question answer operatorthank operator instruction first question come kevin caliendo ubs please go aheadkevin caliendo ubs analyst great thanks taking question appreciate color guidance want delve little bit pharma growth increase much related optum cost onboarding cost associated bringing contract like board meaning dilute impact year quick followup noticed mention optum part medsurg guidance belief also potential contract win incremental contract win true impact yearbritt vitalone chief financial officer thanks question kevin start maybe go reverse order win optum contract certainly pleased extend expand partnership brian mentioned pharmaceutical related think next year optum included guide know specifically talk customer contract detail provided specific contribution optum intend going forward recent contract win incurred cost yet related transition expect cost transition material certainly included guidancerachel rodriguez vice president investor relation next question pleaseoperatornext allen lutz bank america please go aheadallen lutz bank america merrill lynch analyst good afternoon thanks taking question one britt want ask prior authorization business rsts heard employer coverage glps doubled year year amount employee coverage glp twice high even though amount glp dispensing lower would still expected prior authorization activity business would benefited pretty significantly calendar q glprelated prior authorization get pushed calendar q impact change speak growth rate business broadly thanksbritt vitalone chief financial officer yeah thanks question start certainly brian could add think talked segment past many different thing go segment one pl business pl business talked past slightly half revenue mentioned comment pl performance lower prior year various customer contract consideration certainly pleased seeing prior authorization business continue see growth business continue see growth fiscal fourth quarter well make number investment talked also made investment future year continue growth continue value providing customer underlying strong year business grew bottom line year year great momentum prior authorization business part access solution growth first quarter mentioned slower pl performance continue make investment business future growthbrian tyler chief executive officer relates payer frankly employer behavior relates coverage drug think got probably bifurcate diabetes mature indication weight loss tied emerging tracking followon condition may may applicable think early day employer payer figuring handle across spectrum quite different rachel rodriguez vice president investor relation next question pleaseoperatornext lisa gill jpmorgan please go aheadlisa gill jpmorgan chase company analyst thanks much want go back pharmaceutical operating profit go back look kind longterm outlook talked growth talking one know want talk specific customer tied new customer win something else propelling think optum comment started relationship last year increased scope service sourcing distribution oncology maybe help u understand one winning business secondly look optum versus maybe client incremental opportunity see optum going forward brian tyler chief executive officer thank lisa appreciate question look obviously really excited get privilege opportunity expand relationship optum think testament differentiated service solution breadth diversified healthcare service offering optum big complicated entity lot service lot solution really happy opportunity think reflection investment made past several year efficiency core operation commitment continuing make investment efficiency innovation thinking use tool solve different problem much today distribution agreement servicing optum home delivery optum infusion optumcare specialty pharmacy broad regard think reflection past investment made distribution portfolio capability offerbritt vitalone chief financial officer lisa maybe answer question maybe would start little bit foundation building think yous pharma segment last four year adjusted operating profit grown compound annual growth rate really right middle longterm target provided longterm target reason expect sustainable growth rate segment certainly pleased growth saw fy exclude impact covidrelated program fy segment grew certainly lot momentum business enter fy brian mentioned certainly pleased opportunity serve optum well business making lot investment business expertise continuing add term sourcing capability providing value back customer lot momentum segment think growth rate outlined continuation momentum seen last several yearsrachel rodriguez vice president investor relation next question pleaseoperatorand next michael cherny leerink partner please go aheadmike cherny leerink partner analyst good afternoon thanks taking question congratulation really nice guide think forward beyond want ask little bit oncology side asset maybe wrap secondary question continue scale stuff like yous alongside obviously everything inside pharma solution pharma service segment think totality asset ability build platform postal ability also utilize evergrowing free cash flow continue drive inorganic growth top organic within portfolio broadbased oncology asset best area continue expand beyond already arebrian tyler chief executive officer yeah thank michael appreciate talked many time capital allocation strategy first priority strategy invest grow business either internal development investment innovation inorganic opportunity certainly look inorganic opportunity like tightly aligned articulated strategy associated proper financial return course oncology one growth area one growth priority pretty significant player oncology space general leading player community oncology space familiar lot would call emerging tool technology company anywhere find asset aligned strategy community oncology think additive either footprint yous oncology leading emr add capability data insight business accelerates clinical trial would much sweet spot u britt actually referenced comment internal stuff around ai made small acquisition past bring u capability area helping u improve efficiency serving patient improving practice quality lifestyle basically oncologist practice part yous oncology think part overall formula really supporting enabling well quite frankly record growth last yearrachel rodriguez vice president investor relation next question pleaseoperatorand next charles rhyee td cowen please go aheadcharles rhyee td cowen analyst yeah thanks taking question wanted circle back rxts obviously looking really positive outlook thinking preliminary fiscal guide kind gave segment last quarter final guide actually little bit better sort comment driving sort increased optimism solely thinking maybe glps maybe talk sort kind gain relay health relates change healthcare outage comment would helpful thanksbritt vitalone chief financial officer thanks question start aop growth guide provided fy really right range seen growth last four year maybe slightly compound annual growth rate business operating profit since fy growth rate provided year really kind right line intend continue make investment business go forward develop additional solution capability customer expect technology solution service continue grow last year value providing partner continuing resonate see stable prescription growth really underpinning lot program solution growth rate expect next year really line able deliver last several continue brian talked use free cash flow invest growth opportunity go forwardrachel rodriguez vice president investor relation next question pleaseoperatorthe next eric percher nephron research please go aheaderic percher nephron research analyst thank question relative competitive intensity specifically contract movement seen think optum real concern contract could even outsourced element specialty could outsourced yet come also seen cv outsourcing scale question would believe developed scale advantage main specialty unique relative distributor important specialty footprint driving value led significant gainsbrian tyler chief executive officer thanks eric well look going comment much competitive set say made pretty significant investment business modernize distribution infrastructure think cold chain handle cold chain efficiently highly compliant distribution network certainly scale business business year scale tend help really come back fact made investment core distribution excellence clearly understand piece market quite well think solutionoriented valueadded kind partner try paint broad picture could relationship could grow relationship time using array capability represented within mckesson britt vitalone chief financial officer yeah eric would add think strategy executed last several year disciplined focused really growing capability oncology pharma service including investment brian spoke term distribution network breadth capability today significant year ago value able provide investment made acquisition made like oncology example believe value attractive breadth capability wellrachel rodriguez vice president investor relation next question pleaseoperatorthe next stephanie davis barclays please go aheadstephanie davis barclays analyst hey guy thank taking question congrats really good guidance hoping get little bit color nature biopharma investment making prescription transaction business kind nature whether recurring expense like head count compared nearterm pocket like platform development anything give u brian tyler chief executive officer yeah start britt want add anything mean pretty differentiated set asset business scale multiple scaled network call includes connectivity provider workflow much fundamentally think part job continue innovate enhance value return product provide biopharma continue solve new problem historically always invested business see opportunity ahead u afraid increase investment run think differentiated asset allow u solve problem unique way investment technology probably would sayrachel rodriguez vice president investor relation next question pleaseoperatorthe next elizabeth anderson evercore isi please go aheadelizabeth anderson evercore isi analyst hi guy thanks much question congrats nice guide intrigued comment med surg segment sort thinking data use asset new acquisition made seems like little bit shift sort additional valueadded service segment could give little bit color sort see evolving next couple yearsbrian tyler chief executive officer sure mean many way thought compile foundational data investment u like business also thought given data set transaction set reside company could augment add accelerate chose first use case medical business extensive hundred thousand relationship provider data complement already strong provider data service offering think augment unlock unique value footprint reach medsurg making investment thesis rachel rodriguez vice president investor relation next question pleaseoperatorthe next daniel grosslight citi please go aheaddaniel grosslight citi analyst hey guy thanks taking question want go back question charles asked rcs really top line seeing material acceleration growth next year mentioned adjusted operating income kind line historically imply bit degradation margin hoping could put finer point growth acceleration top line margin compression seeing mix shift lowermargin business increased investment making color would great thanksbritt vitalone chief financial officer thanks question answer growth seeing next year top line accelerated growth pl business talked pl business generally represents little half revenue segment le adjusted operating profit expect win additional business next year see customer continue grow revenue faster rate seen prior year given mix represents segment driving faster top line lower margin rate bottom line particular business pl business underlying technology business continuing grow consistent manner really pleased growth seeing seeing mix impact fy pl businessrachel rodriguez vice president investor relation next question pleaseoperatornext erin wright morgan stanley please go aheaderin wright morgan stanley analyst great thanks wanted get little bit color seeing embedded guidance term pricing environment yous pharma business assumption making term generic pricing trend environment seeing well kind branded side know le swing factor playing relative expectation thanksbritt vitalone chief financial officer sure happy answer question think pricing environment branded product going anticipation consistent seen past several year stable competitive branded price environment generic space look drive value customer working operation looking drive lowest cost highest availability supply believe outlook fy expect see competitive stable environment generic space well see lot change environment branded generic pricing outlook versus fy anticipate continue drive good value generic space customersrachel rodriguez vice president investor relation think time probably one questionoperatorcertainly question come stephen baxter well fargo please go aheadstephen baxter well fargo security analyst thanks question know much guidance wanted ask one quarter pharma revenue growth rate wondering could help u think impact might seen insulin list price change quarter sound like probably headwind revenue growth rate contribution commercial covid vaccine quarter mindful thanksbritt vitalone chief financial officer yeah nothing really specific call steve relates covid vaccine mentioned lapping covid program last year commercial vaccine perspective lower contribution saw third quarter really nonmaterial amount contribution fourthquarter resultsbrian tyler chief executive officer hey well thanks everyone joining call evening appreciate ongoing interest support mckesson want thank operator facilitating call mckesson reported solid performance fiscal really pleased momentum across segment continued commitment company priority looking ahead remain confident ability consistently execute strategy support sustain growth long term excited opportunity grow customer drive innovation differentiated portfolio service solution importantly service mission advance improve healthcare every setting appreciate everyone time hope terrific eveningoperatoroperator signoff duration minutescall participantsrachel rodriguez vice president investor relationsbrian tyler chief executive officerbritt vitalone chief financial officerkevin caliendo ubs analystallen lutz bank america merrill lynch analystlisa gill jpmorgan chase company analystmike cherny leerink partner analystcharles rhyee td cowen analysteric percher nephron research analyststephanie davis barclays analystelizabeth anderson evercore isi analystdaniel grosslight citi analysterin wright morgan stanley analyststephen baxter well fargo security analyst mck analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends mckesson motley fool disclosure policy